



DECEMBER 18, 2024

ACIP Recommendations: COVID-19 Vaccine

Advisory Committee on Immunization Practices (ACIP)

KEY POINTS

- The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
- These recommendations become official CDC policy once adopted by CDC's Director.
- Learn about current and historical ACIP recommendations for COVID-19 vaccine.

Published in Morbidity and Mortality Weekly Report (*MMWR*)

The [Advisory Committee on Immunization Practices \(ACIP\)](#) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

Keep Reading:

[See Clinical Considerations for Use of COVID-19 Vaccines](#)

CURRENT COVID-19 Vaccine Recommendations

MMWR, December 12, 2024. Vol 73 (49); 1118-1123

[Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024](#)
[Print version](#)

MMWR, September 10, 2024. Vol 73 (37);819-824

[Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025.](#)
[Print version](#) [PDF](#)

ARCHIVED COVID-19 Immunization Publications

For your convenience, these archived publications can be used for historical and research purposes.

MMWR, April 25, 2024, Vol 73(16);377-381

[Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024](#)
[Print version](#) [PDF](#)

MMWR, October 20, 2023, Vol 72(42);1140–1146

[Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendation of the Advisory Committee on Immunization Practices — United States, September 2023](#)
[Print version](#) [PDF](#)

MMWR, June 16, 2023, Vol 72(24);657–662

[Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023](#)
[Print version](#) [PDF](#)

MMWR, November 11, 2022, Vol 71(45); 1436-1441

[Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022](#) | MMWR (cdc.gov).

[Print version](#) [PDF](#)

MMWR, August 4, 2022, Vol 71(31); 988-992

[Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022](#)

[Print version](#) [PDF](#)

MMWR, June 28, 2022, Vol 71(26);859–868

[Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022](#)

[Print version](#) [PDF](#)

MMWR, March 18, 2022, Vol 71(11);416–421

[Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022](#)

[Print version](#) [PDF](#)

MMWR, January 21, 2022, Vol 71(3);90–95

[Use of the Janssen \(Johnson & Johnson\) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021](#)

[Print version](#) [PDF](#)

MMWR, November 5, 2021, Vol 70(45);1579–1583

[Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021](#)

[Print version](#) [PDF](#)

MMWR, November 5, 2021, Vol 70(44);1545–1552

[Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021](#)

[Print version](#) [PDF](#)

MMWR, September 24, 2021, Vol 70(38);1344–1348

[Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021](#)

[Print version](#) [PDF](#)

MMWR, August 13, 2021, Vol 70(32);1094-1099

[Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen \(Johnson & Johnson\) and mRNA COVID-19 Vaccines \(Pfizer-BioNTech and Moderna\): Update from the Advisory Committee on Immunization Practices — United States, July 2021](#)

[Print version](#) [PDF](#)

MMWR, July 9, 2021, Vol 70(27);977–982

[Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021](#)

[Print version](#) [PDF](#)

MMWR, May 14, 2021, Vol 70(20);749–752

[The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021](#)

[Print version](#) [PDF](#)

MMWR, April 30, 2021, Vol 70(17);651-656

[Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen \(Johnson & Johnson\) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021](#)

[Print version](#) [PDF](#)

MMWR, March 2, 2021, Vol 70(9);329–332

[The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021](#)

[Print version](#) [PDF](#)

MMWR, December 22, 2020, Vol 69(5152);1657-1660

[The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020](#)

[Print version](#) [PDF](#)

MMWR, December 20, 2020, Vol 69(5152);1653-1656

[The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States,](#)

[December 2020](#)

[Print version](#) [PDF](#)

MMWR, December 13, 2020, Vol 69(50);1922-1924

[The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States,](#)

[December 2020](#)

[Print version](#) [PDF](#)

MMWR, December 3, 2020, Vol 69(49);1857-1859

[The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United](#)

[States, 2020](#)

[Print version](#) [PDF](#)

SOURCES

CONTENT SOURCE:

[National Center for Immunization and Respiratory Diseases \(NCIRD\)](#)